ArticleJournal of Zhejiang University. Science. B
Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells.
Article in Journal of Zhejiang University. Science. B. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Combining tissue-derived microRNAs with clinical risk models for prediction of HCC recurrence after liver transplantation: A proof-of-concept study.Scientific reports · 2026Article
- Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach.NAR cancer · 2025Article
- C6 Ceramide Inhibits Canine Mammary Cancer Growth and Metastasis by Targeting EGR3 through JAK1/STAT3 Signaling.Animals : an open access journal from MDPI · 2024Article
- Construction of Metastasis-Specific Regulation Network in Ovarian Cancer Based on Prognostic Stemness-Related Signatures.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells.Scientific reports · 2022Article
- [Role of exosomal miRNA in tumor progression and its possible mechanism].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- XIST promotes apoptosis and the inflammatory response in CSE-stimulated cells via the miR-200c-3p/EGR3 axis.BMC pulmonary medicine · 2021Article
- Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas.Scientific reports · 2020Article
- LINC00680 and TTN-AS1 Stabilized by EIF4A3 Promoted Malignant Biological Behaviors of Glioblastoma Cells.Molecular therapy. Nucleic acids · 2020Article
- Identification of Key Differentially Expressed Transcription Factors in Glioblastoma.Journal of oncology · 2020Article
- A Risk Prediction Model for Breast Cancer Based on Immune Genes Related to Early Growth Response Proteins Family.Frontiers in molecular biosciences · 2020Article
- MicroRNA‑718 serves a tumor‑suppressive role in non‑small cell lung cancer by directly targeting CCNB1.International journal of molecular medicine · 2020Article
- Overexpressing miR‑335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer.International journal of oncology · 2019Article
- Article
- An Update on Novel Therapeutic Warfronts of Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in the Future.Oxidative medicine and cellular longevity · 2019Review
- MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis.PloS one · 2018Article
- Article
- Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas.Journal of Zhejiang University. Science. BArticle
- A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth.Journal of Zhejiang University. Science. BArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatocellular carcinoma (HCC) is still one of the most common death-related malignancies worldwide. Because the way onset and progression are hidden most, HCC diagnoses are made at an advanced stage, when they are unsuitable for surgical resection. MicroRNAs are a class of small non-coding RNAs, participating in many aspects of cancers. In this study, we tried to establish the role of microRNA-718 (miR-718) in the malignant phenotype of HCC cells and its possible role in HCC diagnosis.
methodsHere we first used a methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Transwell migration and invasion assays, and colony formation assay to evaluate the impact of miR-718 on the malignant phenotypes of HCC cells. Then, we used bioinformatic methods to predict the target gene of miR-718 and used green fluorescence protein (GFP) reporter assay, Western blot, and quantitative real-time polymerase chain reaction (qRT-PCR) to validate the regulation relationship. Finally, we determined the role of the target gene in the HCC phenotype.
resultsWe found that the expression of miR-718 was significantly reduced in various HCC cell lines and HCC tissues. Re-expression of miR-718 significantly reduced the cellular viability and colony formation ability as well as inhibited the migration and invasion abilities of HCC cell lines. Early growth response protein 3 (EGR3) is a direct target of miR-718 and is negatively regulated by miR-718. EGR3 could increase the viability and proliferation of HCC cells, and promot the migration and invasion of HCC cells.
conclusionsmiR-718 acts as a tumor suppressive microRNA in HCC via regulating the expression of EGR3, which may provide a new diagnostic marker and treatment target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.